Drug major Sun Pharma today announced successful phase three clinical trial results for 'Seciera', an under development drug for the treatment of dry eye disease.
Seciera is being developed by Ocular Technologies, a company recently acquired by Sun Pharma.
Following this acquisition, Sun Pharma owns exclusive, worldwide rights to Seciera and is developing it to commercialise for global markets including the US, Europe, and Japan, as well as several emerging markets.
Also Read
"We are happy to see the early onset of action and strong efficacy results for Seciera. These results are highly encouraging for millions of Dry Eye patients across the globe who are yet to find relief for their condition," Sun Pharmaceutical Industries Ltd Managing Director Dilip Shanghvi said in a statement.
The company looks forward to discussing these results with USFDA and agree on next steps for the programme, he added.
"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic dry eye market, which is expected to reach USD 5 billion by 2020," Jerry St Peter, Vice President and Head of Sun Ophthalmics said.
Seciera has the potential to strengthen the company's emerging ophthalmics pipeline, which includes the recent launch of BromSite and late stage development programmes for Xelpros and DexaSite, he added.
Sun Pharma shares today ended at Rs 637.60 apiece on the BSE, up 0.25 per cent from previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
